Hector Sanchez, MD
Internal Medicine · Wilmington, NCNPI 1124446513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,519 of the $193,154 with a category attached, or 83.6%. AstraZeneca accounts for 65.5% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $78,244, more than ten times the $178 reported in 2019. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $547.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$127K
- Sanofi$29K
- Amgen$20K
- Verona Pharma, Inc.$13K
- GSK$1K
- Boehringer Ingelheim$658
- plus $2K from 27 others
Across 64 payments — averaging $9034.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$311K
- AstraZeneca$169K
- GSK$81K
- Boehringer Ingelheim$15K
- Verona Pharma, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $500 from 1 others
What the payments were for
- Consulting fees$1,5151%
- Speaking & faculty fees$161,51984%
- Travel & lodging$19,18510%
- Food & beverage$10,6866%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 128 | $126,590 |
| Sanofi | 30 | $28,818 |
| Amgen | 28 | $20,353 |
| Verona Pharma, Inc. | 13 | $13,320 |
| GSK | 43 | $1,079 |
| Boehringer Ingelheim | 21 | $658 |
| United Therapeutics Corporation | 7 | $391 |
| Regeneron Healthcare Solutions, Inc. | 16 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $231 |
| Jazz Pharmaceuticals Inc. | 5 | $167 |
| Pulmonx Corporation | 8 | $165 |
| ANI Pharmaceuticals, Inc. | 7 | $129 |
| Merck | 5 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 5 | $96 |
| Actelion Pharmaceuticals US, Inc. | 3 | $74 |
| Mylan Specialty L.p. | 3 | $65 |
| Grifols USA, LLC | 3 | $60 |
| Grifols Shared Services North America, Inc. | 1 | $58 |
| Gilead | 2 | $46 |
| Medtronic | 2 | $42 |
| Viatris Specialty LLC | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Resmed Corp | 1 | $31 |
| Stryker | 1 | $25 |
| Pfizer | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,154 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $245,673 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 262 | $223,674 |
| TezspireTezepelumab-Ekko | 46 | $194,400 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $120,902 |
| Dupixent PenDupilumab | 28 | $111,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $73,175 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $51,993 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $45,069 |
| Spiriva RespimatTiotropium Bromide | 65 | $40,259 |
| NucalaMepolizumab | 11 | $37,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $35,956 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $23,603 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,380 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $7,647 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $5,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $1,079 | $360,903466 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $658 | $331,001163 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $126,590 | $291,177234 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $231 | $120,90212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wilmington
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.